M. E. G. Cantafio

Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo

K. Anderson, N. Munshi, P. Tassone, 2015, Leukemia.

In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma

M. Cannataro, P. Guzzi, P. Tassone, 2013, Oncotarget.

Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity

N. Munshi, P. Tassone, P. Tagliaferri, 2018, Leukemia.

Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence

M. Negrini, N. Munshi, P. Tassone, 2012, Clinical Cancer Research.

MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells

N. Munshi, C. Mignogna, P. Tassone, 2017, Leukemia.

BET inhibitors (BETi) influence oxidative phosphorylation metabolism by affecting mitochondrial dynamics leading to alterations in apoptotic pathways in triple-negative breast cancer (TNBC) cells.

M. Pisanu, A. Ciarrocchi, E. Iorio, 2024, Cell proliferation.

Therapeutic vulnerability of multiple myeloma to MIR17PTi, a 1 first-in-class inhibitor of pri-mir-17-92 2

P. Tagliaferri, A. Neri, M. Fulciniti, 2018 .